{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010301","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.206427+00:00","generated_at":"2026-06-14T18:01:16.184750+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"GlycoMimetics stockholders elect all director nominees, ratify auditor, approve say-on-pay","bullets":["Three director nominees elected: Andrews (36.2M for, 0.5M withheld), Goldberg (32.6M/4.0M), Pearson (36.3M/0.4M); 14.2M broker non-votes.","Ratification of Ernst & Young as auditor approved: 50.3M for, 0.5M against, 0.05M abstained.","Advisory vote on executive compensation approved: 36.1M for, 0.4M against, 0.1M abstained; 14.2M broker non-votes.","Approximately 79% of outstanding shares (50.9M of 64.2M) represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010301","json":"https://secwatch.observer/filing/0001558370-23-010301.json","markdown":"https://secwatch.observer/filing/0001558370-23-010301.md","text":"https://secwatch.observer/filing/0001558370-23-010301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/glyc-20230519x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:01:16.184750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18bdc45736e0e4979fd4c5dba24c9242f8c3c141","claim":"CRESCENT BIOPHARMA, INC. shareholders approved To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 3: To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. The votes were cast as follows: ​ Votes For Votes Against Abstained Approved, on an advisory basis, the executive compensation. 36,116,823 ​ 435,570 ​ 112,283 ​ Broker Non-Votes: 14,198,293.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm","confidence":0.98,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"c26aed0e386b55a970b434ac7d72623eb8b7253f","claim":"CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: ​ Votes For Votes Against Abstained Ratification of appointment of Ernst & Young 50,337,103 ​ 474,059 ​ 51,807","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm","confidence":0.98,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"cb624e21b97e5c61b8bb6a2470d0806d492ea5f4","claim":"CRESCENT BIOPHARMA, INC. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: ​ Name Votes For Votes Withheld Patricia Andrews 36,190,925 ​ 473,751 Mark Goldberg, M.D. ​ 32,642,583 ​ 4,022,093 Timothy Pearson ​ 36,279,306 ​ 385,370 ​ ​ Broker Non-Votes: 14,198,293. ​ All nominees were elected.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm","confidence":0.98,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}